[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2–3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial

Ferone D, Pavel ME, Herrmann K, Kunz PL, Myrehaug S, Halperin D, Chasen B, Capdevila J, García-Burillo A, Tafuto S, Lastoria S, Oh DY, Yoo C, Falk S, Halfdanarson TR, Sansovini M, Gerard L, Deshayes E, Filice A, Folitar I, Zhang Y, de Herder WW, Singh S (2026)

Publication Type: Journal article

Publication year: 2026

Journal

Book Volume: 98

Article Number: 104109

DOI: 10.1016/j.eclinm.2026.104109

Abstract

Background: In the phase 3 NETTER-2 study, first-line [¹⁷⁷Lu]Lu-DOTA-TATE (hereafter ¹⁷⁷Lu-DOTATATE) significantly improved progression-free survival in patients with advanced, well-differentiated, higher grade 2–3 (Ki67 ≥10% and ≤55%), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Median progression-free survival was 22·8 months (95% CI 19·4–not estimable [NE]) with ¹⁷⁷Lu-DOTATATE vs 8·5 months (7·7–13·8) in the control arm. Here, we report subgroup analyses, including preplanned assessments of efficacy by NET grade (G) and site of origin; further post-hoc analyses are reported in the main text. Methods: In this open-label, parallel-group study, patients from nine countries were randomised 2:1 to receive four cycles of ¹⁷⁷Lu-DOTATATE plus octreotide long-acting repeatable (LAR) 30 mg every 8 weeks then octreotide LAR 30 mg every 4 weeks, or high-dose octreotide LAR 60 mg every 4 weeks. The primary endpoint (progression-free survival) was previously reported. Tumours were assessed at baseline, week 16, week 24, then every 12 weeks until disease progression or death. Preplanned subgroup analyses used blinded independent centrally reviewed data. The study is registered with ClinicalTrials.gov, NCT03972488, and is completed. Findings: Between Jan 22, 2020, and Oct 13, 2022, 261 patients were screened; 35 were excluded due to screen failure, and 226 were randomised. ¹⁷⁷Lu-DOTATATE (n = 151) reduced risk of disease progression/death vs control (n = 75) regardless of NET grade/origin (hazard ratio [95% CI]: G2 NET 0·31 [0·18–0·53]; G3 NET 0·27 [0·14–0·49]; pancreatic NET 0·34 [0·20–0·56]; gastrointestinal NET 0·23 [0·12–0·46]). Median progression-free survival in months (95% CI) with ¹⁷⁷Lu-DOTATATE was: G2 NET 29·0 (21·8–NE); G3 NET 22·2 (13·9–27·8); pancreatic NET 19·4 (16·6–24·9); gastrointestinal NET NE (22·6–NE). ¹⁷⁷Lu-DOTATATE improved objective response rate vs control regardless of NET grade/origin. Interpretation: These findings support the use of first-line ¹⁷⁷Lu-DOTATATE for patients with advanced, well-differentiated, higher grade 2–3 (Ki67 ≥10% and ≤55%), somatostatin receptor-positive GEP-NETs, and for whom chemotherapy is not considered the most appropriate treatment option, regardless of NET grade (2/3) or origin (pancreas/gastrointestinal). Funding: Advanced Accelerator Applications, a Novartis Company.

Authors with CRIS profile

Involved external institutions

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Italy (IT) Seoul National University (SNU) / 서울대학교 Korea, Republic of (KR) Asan Medical Center / 서울아산병원 Korea, Republic of (KR) University Hospitals Bristol NHS Foundation Trust United Kingdom (GB) Mayo Clinic United States (USA) (US) Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) Italy (IT) Hôpital Edouard Herriot France (FR) University of Montpellier / Université Montpellier France (FR) Azienda Unità Sanitaria Locale die Reggio Emilia Italy (IT) Novartis AG Switzerland (CH) Erasmus University Medical Center (MC) Netherlands (NL) Sunnybrook Health Sciences Centre Canada (CA) University of Genova / Università degli Studi di Genova Italy (IT) Universität Duisburg-Essen (UDE) Germany (DE) Yale University United States (USA) (US) Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron Spain (ES) University of Texas MD Anderson Cancer Center United States (USA) (US)

How to cite

APA:

Ferone, D., Pavel, M.E., Herrmann, K., Kunz, P.L., Myrehaug, S., Halperin, D.,... Singh, S. (2026). [177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2–3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial. EClinicalMedicine, 98. https://doi.org/10.1016/j.eclinm.2026.104109

MLA:

Ferone, Diego, et al. "[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2–3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial." EClinicalMedicine 98 (2026).

BibTeX: Download